ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
Daiichi Sankyo Co Ltd 4568
News
-
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Fusion Pharma climbs as analysts flag radiopharmaceutical company as potential merger target
AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment
Trending: Merck, Daiichi Sankyo Sign Development, Commercialization Deal
Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck
Daiichi Sankyo Shares Jump on Multibillion-Dollar Drug Development Deal With Merck
Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion
AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive
AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU
AstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control Rates
AstraZeneca shares slump after Phase 3 lung cancer drug study
AstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer Patients
AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial